Afferent Strikes a Good Deal with Stryker
In January, Stryker made an equity investment in neurostimulation start-up Afferent, operating in stroke rehabilitation. The deal is part of Stryker's growth plans to invest in emerging markets that are adjacent to core business segments. For Afferent, the partnership is validation of its unique platform, which stimulates afferent (incoming) rather than efferent (outgoing) nerve centers.
You may also be interested in...
Myomo is capitalizing on the growing tide of scientific evidence that patients have the ability to recover motor function following neurological trauma, such as stroke. The first product from its NeuroRobotics platform is the e100 NeuroRobotic System, a lightweight robotic brace that slides onto the arm and helps improve the patient's mobility by enabling him to initiate and control movement of partially paralyzed muscles by using his own biological signals.
Intelect Medical brings together a patent portfolio from the Cleveland Clinic and Cornell's Weill Medical College, and a management team experienced in neuromodulation, to usher in a new generation of deep brain stimulation. The start-up's initial target markets are traumatic brain injury and stroke.
A brief discussion of a few new companies in stroke management and prevention.